Clinical trials: Liver, active
Hepatocellular Carcinoma (HCC)
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
To evaluate HAIC combined with Sintilimab plus bevacizumab biosimilar for advanced hepatocellular carcinoma.
- Trial name
- NCT06860490
- Testing
- Sintilimab, Bevacizumab Biosimilar, HAIC
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Fudan University
Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.
This is a retrospective cross-sectional research intended to explore the utility of LIVERFASt in the clinical pathways for the detection of liver fibrosis and steatosis in comparison with the Magnetic Resonance Elastography (MRE)…
- Conditions
- Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Liver Disease
- Trial name
- LFMRECT (NCT06797596)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fibronostics USA, Inc
Non-small Cell Lung Cancer, EGFR Mutant Advanced Non-small Cell Lung Cancer
Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
The goal of this clinical trial is to learn if the combination therapy with SKB264 and anlotinib works to treat EGFR-TKI-resistant, liver-metastatic non-squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT07545213
- Testing
- SKB264
- Where
- China
- Volunteers
- 27 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
NAFLD, Diabetes
DIAbetes and NAFLD
Non-alcoholic hepatic steatosis (NAFLD) is characterised by the excessive accumulation of triglycerides in the liver and is often associated, in the absence of significant alcohol consumption, with insulin resistance and…
- Conditions
- NAFLD, Diabetes, NASH, Fibrosis, Liver
- Trial name
- DIANA (NCT06315361)
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Nonalcoholic Fatty Liver Disease, Physician
Patient and Physician Perspectives on Non-Alcoholic Fatty Liver Disease
This trial studies patient and physician perspectives on non-alcoholic fatty liver disease. Using questionnaires and interviews, this trial may help researchers understand physicians' knowledge about the diagnosis, prognosis…
- Trial name
- NCT04132440
- Testing
- Interview, Questionnaire Administration
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma (HCC)
Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths globally, with Native Hawaiian and Pacific Islander (NHPI) populations experiencing significantly higher mortality rates compared to other groups in Hawaii.
- Trial name
- NCT07075120
- Testing
- Ipilimumab and Nivolumab, Stereotactic Body Radiotherapy (SBRT)
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Hawaii
Hepatocellular Carcinoma, Hepatocellular Cancer
Patients With Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide and is frequently diagnosed at an advanced stage, resulting in limited therapeutic options.
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Liver Diseases, Liver Cancer
- Trial name
- FORCE (NCT07690683)
- Testing
- Fecal microbiota transplantation performed via colonoscopy.
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Healthy
A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function
This study is being done to learn more about an investigational medicine called PF-08653944. The goal is to understand how the body handles the medicine and to check its safety after a single dose.
- Trial name
- NCT07519135
- Testing
- PF-08653944
- Where
- 3 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Pfizer
Liver Cancer
Development of a Risk Prediction Model for Immune-Targeted Therapy-Related Diarrhea in Patients With Hepatocellular Carcinoma Based on TCM Constitutional Types: A Prospective Cohort Study
Immune checkpoint inhibitors combined with anti-angiogenic targeted agents have become the first-line standard therapeutic regimen for advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT07741903
- Volunteers
- 500 people
- Sponsor
- Affiliated Hospital of Chengde Medical University
Colorectal Neoplasms, Neoplasms
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Background: Cancers that begin in the colon, adrenal glands, or bile ducts may spread to the liver. These liver tumors are often treated using a hepatic artery infusion (HAI) pump.
- Conditions
- Colorectal Neoplasms, Neoplasms, Intrahepatic Cholangiocarcinoma, Adrenocortical Carcinoma
- Trial name
- NCT07715903
- Testing
- Carfilzomib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Acute Liver Failure, Wilson Disease
Daily Versus Alternate Day Plasma Exchange in Wilson Disease With Acute Liver Failure in Children
Wilson disease in children has a varied presentation. Wilson disease with acute liver failure is associated with very high mortality and morbidity.
- Trial name
- NCT06698991
- Testing
- Plasma Exchange, Standard Medical Treatment
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatocellular Carcinoma, Renal Cell Carcinoma
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread.
- Conditions
- Hepatocellular Carcinoma, Renal Cell Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Carcinoma Primary Differentiated
- Trial name
- NCT07252661
- Testing
- ACC-1898
- Volunteers
- 40 people
- Sponsor
- AccSalus Biosciences, Inc.
Hepatitis D, Hepatitis B
Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)
Portal hypertension (PH) is one of the key drivers of clinical deteoration in patients with liver cirrhosis. It has been demonstrated that antiviral therapy in patients with chronic hepatitis C infection leads to a decrease of PH…
- Conditions
- Hepatitis D, Hepatitis B, Portal Hypertension, Liver Cirrhosis
- Trial name
- IMPHROVE-D (NCT04863703)
- Testing
- Bulevirtide
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- Hannover Medical School
Cholangiocarcinoma, Hepatocellular Carcinoma
Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma
The main objective is to describe the evolution of patients treated for a primary malignant hepatobiliary tumor (hepatocellular carcinoma or cholangiocarcinoma) over the long course.
- Trial name
- CHC/CC (NCT04340986)
- Where
- France
- Volunteers
- 1,250 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
This phase Ib trial studies the side effects and best dose of guadecitabine and how well it works when given together with durvalumab in treating patients with liver, pancreatic, bile duct, or gallbladder cancer that has spread…
- Conditions
- Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type, Metastatic Pancreatic Adenocarcinoma, Recurrent Cholangiocarcinoma
- Trial name
- NCT03257761
- Testing
- Durvalumab, Guadecitabine
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- University of Southern California
HEPATITIS C (HCV), Incarceration
Implementing Low-Barrier HCV Treatment in a Jail Setting
The goal of this clinical trial is to learn whether a low-barrier treatment program can help people with hepatitis C virus (HCV) who are in jail start and complete treatment more easily.
- Conditions
- HEPATITIS C (HCV), Incarceration, Injection Drug Use, Implementation Science
- Trial name
- MINMON-J (NCT06953479)
- Testing
- Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Community Health Worker
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Lifespan
Liver Transplant Rejection, Liver Transplant Failure and Rejection
Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients
Liver transplantation is a lifesaving procedure; however, there are chances that the body may reject the organ following liver transplantation, and this remains a significant concern.
- Trial name
- NCT06153641
- Testing
- N/A-Observational Study
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- St. Louis University
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
The purpose of this study is to determine whether the combination of a neoantigen vaccine targeting the DNAJB1-PRKACA fusion kinase in combination with DRP-104, Nivolumab and Ipilimumab is safe and yields a clinically compelling…
- Trial name
- NCT07430202
- Testing
- DNAJB1-PRKACA Peptide Vaccine, DRP-104, Nivolumab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Obstructive Sleep Apnea, Metabolic Dysfunction-Associated Steatotic Liver Disease
Association Between Metabolic Associated Fatty Liver Disease and Obstructive Sleep Apnea
Association between Metabolic Associated Fatty Liver Disease and Obstructive Sleep Apnea
- Trial name
- OSA/MAFLD (NCT07716995)
- Volunteers
- 127 people
- Sponsor
- Assiut University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.